Building a Better Future for Xiangjiang: Hunan Xiangjiang New Area Medical Industry Matchmaking Event Successfully Held

October 30,Hunan Xiangjiang New Area Medical Industry Matchmaking Event, Co-Hosted by iFlytek and VCBeat, Successfully Held in ChangshaThis EventFocusing on cutting-edge trends and innovative directions in the healthcare sector, we aim to build an efficient matchmaking platform that precisely connects high-potential, high-quality projects to jointly drive regional development.High-Quality Development of the Medical Industry Cluster.

The event kicked off with attendees watching a promotional video on Xiangjiang New Area to learn about its development history and locational advantages. Subsequently,Zhang Yang, Director of the First Investment Promotion Division, Commerce and Market Regulation Bureau, Hunan Xiangjiang New AreaHe introduced the guests to the general situation and conditions of Xiangjiang New Area, as well as the development of the local medical industry and related policies. He pointed out that Hunan Xiangjiang New Area, as the first national-level new area in central China, boasts abundant scientific and educational resources and a solid industrial foundation in the healthcare sector. In terms of medical industry development, it has formed an industrial system centered on medical devices and traditional Chinese medicine, supported by chemical drugs, biologics, pharmaceutical logistics, and high-end services. Regarding policies, the Hunan Provincial Medical Products Administration and the Administrative Committee of the New Area jointly established the Hunan Xiangjiang New Area Drug Evaluation and Inspection Center, creating a vertically integrated service system to further optimize the business environment. We hope to leverage this collaboration between Iflytek and VCBeata platform for exchange, where all parties can engage in in-depth communication and active collaboration to jointly build a brighter future for the Xiangjiang River.

Liu Liqiang, Deputy Director of the First Investment Promotion Division of the Commerce and Market Regulation Bureau of Hunan Xiangjiang New AreaThe Drug Evaluation and Inspection Center of Hunan Xiangjiang New Area Provides an In-Depth Introduction.He mentioned that the center has established a “high-speed channel” for government-enterprise communication in advance, enhancing the efficiency of evaluation and review, and helping enterprises shorten the time for innovative drugs and medical devices fromthe cycle from R&D to market launch, effectively enhancing the company's market competitiveness.

During the project matchmaking session, the three prospective companies participating in the event sequentially presented introductions covering their basic corporate profiles, proposed projects for local establishment, and specific requirements for implementation.

Nuoyi Mayer is rooted in the fields of tissue engineering and regenerative medicine, committed to becoming an internationally leading provider of comprehensive solutions for regenerative medicine. The company has mastered front-end raw material design and development as well as key process preparation technologies, achieved domestic production of high-end core equipment, and broken through foreign technical barriers. Currently, multiple products featuring “domestic firsts” or “international leading” status have successfully completed clinical trials and been launched on the market. Several products within its comprehensive solution for oral soft and hard tissue regeneration have obtained domestic and international certifications and are commercially available, emerging as a new choice for domestic substitution in the dental field. In the otolaryngology sector, its innovative expandable hemostatic sponge has received approvals from the NMPA, CE, FDA, and Southeast Asian regulatory authorities, while its tissue adhesive has obtained CE certification; both products have been adopted by numerous Grade A tertiary hospitals.

Jianxin Medical focuses on the domestic substitution and innovation of high-end surgical instruments, and has currently achieved one-stop services for independent R&D, production, and sales. The company holds 125 patents, including 48 invention patents, and has successfully developed multiple proprietary original products. Jianxin Medical has established product lines such as ultrasonic soft tissue cutting and hemostasis devices, intelligent dual-engine dynamic hybrid energy surgical systems, dual-frequency ultrasonic lithotripsy systems, and multifunctional coagulation and suction surgical systems. Among these, its ultrasonic soft tissue cutting and hemostasis devices have been commercialized and have received high recognition from industry peers.

Kuanteng Medical is a high-tech enterprise specializing in the research and development, manufacturing, and sales of medical imaging equipment. Adhering to technological innovation, the company provides magnetic resonance imaging (MRI), computed tomography (CT) systems, X-ray devices, and related services to customers worldwide. It has established four R&D centers and five production bases across China, with R&D personnel accounting for over 30% of its workforce. The company holds more than 200 intellectual property rights and has achieved independent R&D and manufacturing for its full product lines of CT, MRI, and digital radiography (DR) equipment, including self-developed and self-produced core components. Kuanteng Medical’s products rank among the top in market share within multiple niche segments in China.

During the exchange session, participants engaged in in-depth discussions on policy implementation and project details. Leaders from relevant departments of Xiangjiang New Area provided responses to issues raised by enterprises, including financing needs and site selection.Zhang Shun, General Manager of the Iflytek Changsha Industry Acceleration Center, stated that the center would serve as a solid foundation for enterprises establishing their presence in the Xiangjiang New Area, providing multiple empowerment services to facilitate rapid growth from a new starting point.

This healthcare and medical industry exchange conference is a new initiative jointly organized by the Iflytek Changsha Industry Acceleration Center and VCBeat, aimed at further amplifying the agglomeration effect of the healthcare and medical industry ecosystem in the Xiangjiang New Area and boosting the development of the local healthcare and medical industry.Since its launch, the Changsha Industry Acceleration Center has incubated more than 60 enterprises, created nearly 800 jobs, and generated an output value exceeding RMB 1.5 billion as of September 30, 2025.

In the future, iFlytek will continue to leverage its leadership in artificial intelligence technology and ecosystem synergy capabilities. By focusing on local advantageous industries, it will promote the integration of technological applications with industrial development, thereby helping Xiangjiang New Area build an influential new highland for the medical and health industry.